Who are the leading innovators in T-cell receptor peptides for the pharmaceutical industry?

MEEFRO May 15, 2023

0 124,533 2 minutes read

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immunotherapy in Pharmaceuticals: T-cell receptor peptides.

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

T-cell receptor peptides is a key innovation area in immunotherapy

T-cell receptors (TCRs) on T-cells play an important role in adoptive T-cell transfer by recognising peptides presented on the major histocompatibility complex (MHC). Antigens are processed endogenously within cells, followed by efficient binding of peptides to MHC molecules and presentation of antigenic peptides on the cell surface. Foreign and neoantigen peptides presented on the cell surface of MHC molecules are recognised by cytotoxic T cells and specifically induce cell death of infected or tumour cells. Recognition is mediated by heterodimeric cell surface TCRs present on T-cells. This TCR has highly variable alpha and beta chains. The somatic recombination process that occurs during thymic maturation results in diverse alpha and beta TCR chains, resulting in a large repertoire of unique TCRs that provide broad pathogen and tumour recognition.

GlobalData’s analysis uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 170+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of T-cell receptor peptides.

Key players in T-cell receptor peptides – an innovative target for therapies in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to T-cell receptor peptides

Source: GlobalData Patent Analytics

Bristol-Myers Squibb (BMS) is the leading patent filer in T-cell receptor peptides. BMS is engaged in the development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is oncology, cardiovascular, immunology, and fibrotic therapeutic projects. BMS is headquartered in New York City, New York.

In terms of application diversity, Lonza Group is the top company, followed by Glycostem Therapeutics and Immatics. By means of geographic reach, Instil Bio holds the top position. Les Laboratoires Servier SAS and Intellia Therapeutics stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.